Existing chemical inhibitors of NK1R are predominantly designed based on the nitrogen-containing scaffold of CP96345 and typically feature a benzyl- or phenyl-substituted
N-heterocycle core structure
31 (Supporting Information Fig. S12). They showed less satisfaction in conditions like analgesia and are often accompanied by multiple adverse effects
32,33. Therefore, it is necessary to provide a highly efficient and low-toxicity NK1R inhibitor with a novel skeleton. Here, we focus on magnolol, a non-nitrogenous natural product belonging to the lignan family, which has been reported to be one of the quality markers of Chaiqin chengqi decoction used for treating AP and alleviating pain
12,34. We examined whether magnolol could target NK1R to ameliorate mitochondrial dysfunction of pancreatic acinar cells and AP. By molecular docking and cellular thermal shift assay, we found that magnolol significantly stabilized NK1R protein under 70 ℃ and 75 ℃ in both Ctrl and SP-stimulated cell lysis in pancreatic acinar cells (
Fig. 5A). This result was confirmed by a small molecule interaction assay, and the data indicated that magnolol could interact with recombinant NK1R protein with high affinity (
KD = 89 μmol/L) (
Fig. 5B). To provide solid evidence supporting the physical interaction between magnolol and NK1R, we designed a small molecular probe of magnolol (
Fig. 5C), termed conjugated-magnolol (cMag). The synthesis of cMag began with the conversion of magnolol to 5,5′-diallyl-2,2′-dihydroxy-[1,1′-biphenyl]-3-carbaldehyde (
1)
via a formylation reaction. Then, (
1) was treated with 2-(prop-2-yn-1-yloxy) ethan-1-amine, followed by a Borch reaction, and generated cMag (Supporting Information Fig. S13). Then the cMag can be conjugated with an azide-containing fluorophore
via the alkyne bond under Cu
2+ catalysis, leading to the red fluorescence emission (
Fig. 5C). Furthermore, through molecular docking analysis, hydrogen bonding interactions were identified between cMag and the binding pocket in the substrate-binding domain of NK1R (PDB:6HLO) (Supporting Information Fig. S14). These interactions confirmed the binding of cMag to NK1R, which is similar to magnolol (
Fig. 5D). The comparable bioactivity of cMag to magnolol was evidenced by its protection against taurolithocholic acid sulfate (TLCS)-induced cell death (
Fig. 5E and F) and ATP reduction (Supporting Information Fig. S15). Next, competitive inhibition of NK1R by cMag or CP96345 was performed on living pancreatic acinar cells. As shown in
Fig. 5G, after the click chemical reaction, cMag with red fluorescence was visualized on the plasma membrane of living pancreatic acinar cells, and this fluorescent signal was significantly decreased in the case of CP96345 pre-incubation (
Fig. 5H). This result indicated the physical interaction of magnolol and NK1R. Additionally,
Tacr1 knockdown significantly increased cellular ATP levels in pancreatic acinar cell lines 266-6 after SP stimulation, and the beneficial effect was not affected by magnolol (Supporting Information Fig. S16). These results suggest that magnolol could improve AP by directly inhibiting NK1R in pancreatic acinar cells. Next, we examined whether magnolol could restore purine nucleotide cycle metabolic enzyme expressions and mitochondrial dysfunction damaged by SP on pancreatic acinar cells. As shown in
Fig. 5I, magnolol could restore the protein levels of ADSS, ADSL, and AMPD. Further, magnolol significantly improved cellular fumarate (Fig. S11), mitochondrial respiration (
Fig. 5J), and morphological changes (
Fig. 5K). Hence, magnolol protected against SP-induced mitochondrial injury by inhibition of NK1R on pancreatic acinar cells.